Evidence map›Paper›PMID 42608506›Full record

ArticleDiscover oncology2026

Molecular characterization of mismatch repair deficient tumors in young Jordanian patients.

Olfat Ahmad, Iyad Sultan, Maysa Hussaini, Osama Alsmadi, Christian Sutter, Steffen Hirsch, Robert J Autry, Christopher Previti, Asta Försti, Benjamin Schwalm and 15 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Olfat AhmadHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Iyad SultanKing Hussein Cancer Center (KHCC), Amman, Jordan.
Maysa HussainiKing Hussein Cancer Center (KHCC), Amman, Jordan.
Osama AlsmadiKing Hussein Cancer Center (KHCC), Amman, Jordan.
Christian SutterInstitute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany.
Steffen HirschHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Robert J AutryHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Christopher PrevitiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Asta FörstiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Benjamin SchwalmHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Lama AbuJamousQatar University, Doha, Qatar.
Nisreen AmayiriKing Hussein Cancer Center (KHCC), Amman, Jordan.
Mayada Abu ShanapKing Hussein Cancer Center (KHCC), Amman, Jordan.
Rola AmareenKing Hussein Cancer Center (KHCC), Amman, Jordan.
Salsabeel AljawabrahFaculty of Medicine, University of Jordan, Amman, Jordan.
Lara FryjatFaculty of Medicine, University of Jordan, Amman, Jordan.
Aya Al-NaimatFaculty of Medicine, University of Jordan, Amman, Jordan.
Areen QaisiFaculty of Medicine, University of Jordan, Amman, Jordan.
Hala AlnaimatFaculty of Medicine, University of Jordan, Amman, Jordan.
David E ReussDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Nicholas R FernandezArthur and Sonia Labatt Brain Tumor Research Centre, Toronto, ON, Canada.
Anirban DasArthur and Sonia Labatt Brain Tumor Research Centre, Toronto, ON, Canada.
Uri TaboriArthur and Sonia Labatt Brain Tumor Research Centre, Toronto, ON, Canada.
Stefan M PfisterHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Christian P SchaafInstitute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany. christian.schaaf@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mismatch repair deficiency (MMRD) contributes substantially to early-onset colorectal carcinoma (CRC) and pediatric malignancies in Jordan. Approximately 19% of CRCs diagnosed in adults younger than 45 years exhibit MMRD by immunohistochemistry (IHC). In pediatric tumors, MMRD accounts for 39% of high-grade gliomas (HGGs) and 44% of CRCs, likely reflecting the increased prevalence of constitutional MMRD (CMMRD) in this highly consanguineous population. However, the molecular characterization of MMRD-associated tumors in the Middle East remains limited. We analyzed 14 Jordanian patients (< 45 years) from 12 families with clinical or IHC evidence of MMRD, including four HGGs and 11 CRCs; five patients were children. Pathogenic or likely pathogenic MMR variants were identified in nine families, including one sibling pair, comprising five frameshift indels, three single nucleotide variants, and one large deletion. A variant of uncertain significance in MSH6 was identified in another sibling pair. Apparent large deletions suggestive of sequencing artifacts in six patients highlighted the need for confirmatory copy number analysis by multiplex ligation-dependent probe amplification. Tumor mutational burden ranged from 2 to 352 variants/Mb (median, 23). Microsatellite instability was low in seven tumors, likely reflecting degraded DNA from older formalin-fixed paraffin-embedded samples. Mutational signatures were concordant with the molecular findings in most cases. Notably, the only ultrahypermutated tumor harbored a canonical somatic POLE p.(Val411Leu) proofreading-domain mutation together with polymerase-associated mutational signatures, consistent with combined MMRD and polymerase proofreading deficiency. This study represents the first comprehensive molecular characterization of MMRD-associated tumors in Jordan.

Indexed as

Colorectal cancerConstitutional mismatch repair deficiency (CMMRD)High-grade gliomaJordan/Middle EastLynch syndromeMismatch repair deficiency (MMRD)

Identifiers

PMID42608506
PMCPMC13481598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.